The company's molecular counter platform accurately counts DNA molecules to detect single-gene disorders such as thalassemia, sickle-cell disease, beta-thalassemia, spinal muscular atrophy, and cystic fibrosis through a simple blood test. By replacing invasive and risky procedures like amniocentesis, BillionToOne's technology is making pre-natal testing more accessible and efficient. The company's mission is to improve disease detection through accurate and affordable molecular diagnostics.